HonorHealth Research Institute

10/18/2026

Word fumbles. Sleep sabotages. Mood swings. 🙃

No, you're not imagining things. These can all be signs of perimenopause, and there are ways to feel more like yourself again.

For World Menopause Day, HonorHealth gynecologist Dr. Khai Ling Tan explains what's happening beneath the surface and the options available to help manage symptoms:

Could hormone changes be affecting your sleep, mood or cycle? Explore perimenopause symptoms and treatment options at HonorHealth.com.

10/17/2026

Heart disease doesn't always follow the script.

Dr. Christina Reuss, cardiologist and medical director of the HonorHealth Women’s Heart Health Program, shares what women need to know about the symptoms that are often overlooked.

❤️ Consider this your sign to pay attention.

Plus: What’s “comorbidity”? + Making sense of fluoride’s role in dental health

10/16/2026

Named Arizona Bioscience Researcher of the Year, Dr. Sunil Sharma and his international team at HonorHealth Research Institute are flipping traditional research on its head to bring breakthrough cancer treatments straight from the lab to the Valley. 🧬✨

10/16/2026

Wish healthcare was on your terms? It can be.

HonorHealth Concierge Medicine at Stonecreek gives each patient personalized, one-on-one care with extended appointments, direct access to the physician, and a team focused entirely on YOU.

Skip the waiting rooms. Get comprehensive annual exams, help managing chronic conditions, preventive care and treatments that fit your life — not the other way around.

Spots are limited. Reserve yours today!

HonorHealth Concierge Medicine at Stonecreek is designed to give you increased access to care for an affordable fee. Learn more about this location

10/15/2026

Start your engines. 🏎️💨

As the official Health and Wellness Partner of , we're revved up and ready to go for the NASCAR Chase Race happening this weekend – Oct. 16–18.

Whether you're cheering from the stands or watching from home, HonorHealth is here to keep our Valley community safe.

Heading to the race? Look for the HonorHealth Care Center right outside Gate 5. We'll be open 24/7, Friday morning through Monday, to deliver full-service, urgent-care-level medical support on and off the track.

Good luck to all the drivers! 🏁🩺

10/15/2026

Scrub up! 🧼🫧

Everybody washes their hands. But at HonorHealth, we treat it like an art form.

While the rest of the world is just trying to get through a quick rinse, our teams know that 20 seconds at the sink is the minimum for keeping our patients and each other safe — and for surgeons, that number can go up to 6 minutes!

Happy Global Handwashing Day to the pros who do it right every single time.

10/14/2026

Fountain Hills is officially painting the town pink for Breast Cancer Awareness Month — and two of our own were first to get the news. 💖

Dr. Stephanie Lindauer and Dr. Sommer Gunia, two of our breast cancer experts, received the official proclamation from the town council, noting that breast cancer is the most common cancer among women.

More than just a town milestone, this month is an opportunity to remember those we've lost, support those currently affected and celebrate every survivor.

10/14/2026

Congratulations to Dr. Priya Radhakrishnan on her recognition as a Master of the American College of Physicians — making her one of only 66 physicians nationwide to earn this elite distinction for 2026–27!

The Mastership of the American College of Physicians (MACP®) is one of the organization’s highest honors, recognizing physicians who have made a meaningful impact on medicine and the patients they serve. It celebrates exceptional leadership, expertise and a lasting commitment to advancing patient care.

Learn more about Dr. Radhakrishnan's inspiring career and impact at HonorHealth and Arizona State University: https://bit.ly/4zr8wvZ

10/13/2026

He's a real-life Doogie Howser. 🩺✨

At just 19 years old, former HonorHealth volunteer Dustin is officially part of the inaugural class at Arizona State University's John Shufeldt School of Medicine and Medical Engineering.

Talk about making your mark early!

10/13/2026

Setting the gold standard for taking care of our own. 🏆

We’re thrilled to earn Gold recognition from the American Medical Association 2026 Joy in Medicine® Program for physician well-being — making us one of only 21 health systems nationwide (and just two in Arizona!) to hit this top-tier milestone.

From peer support and listening rounds to cutting through red tape, we're doing the work to back our docs and advanced practice providers.

Read more about how we're building a stronger culture of care: https://bit.ly/3TWtUtX

10/08/2026

Congratulations to Sunil Sharma, M.D., FACP, M.B.A., director of the Center for Translational Science at HonorHealth Research Institute, on being recognized as AZBio's Arizona Bioscience Researcher of the Year.

Presented during the 2026 AZBio Awards as part of Arizona Bioscience Week, the honor recognizes Dr. Sharma's contributions to biological research, drug discovery and translational science.

Watch the video presented during the awards ceremony:

🎥

Arizona Bioscience Researcher of the Year 2026Sunil Sharma, M.D., ...

10/06/2026

HonorHealth Research Institute has completed its first case involving a new way to treat Type 2 Diabetes, which uses a minimally invasive radiofrequency heated v***r ablation of the mucosa, or inner lining, of the first part of the small intestine.

The procedure, created by Aqua Medical of Pleasanton, Calif., aims to improve diabetes control by endoscopically heating and resurfacing the mucosa of the duodenum — the first several inches of the small intestine, just past the stomach — which research suggests may play a role in blood sugar regulation.

This clinical trial, called RESTORE-1, aims to help those patients whose Type 2 Diabetes is not adequately controlled with medications, diet and exercise. Those eligible for the study must be: age 22-65; have Type 2 Diabetes for at least one year; not currently taking insulin; have a body mass index of 24-40 kilograms; and an HbA1c measure of 7.5-10%. All tests, procedures and clinic visits are free.

What researchers learn from this clinical trial could help provide less invasive treatment options for patients with Type 2 Diabetes, and eventually lead to FDA approval of the RESTORE-1 procedure.

Principal Investigator of this trial is James Swain, M.D., medical director of the Research Institute’s Bariatric/GI Research Division. Endoscopy used in this procedure was conducted by Amar Thosani, M.D., a board certified interventional gastroenterologist.

For more about HonorHealth Research Institute clinical trials: call 833-354-6667; or email [email protected].

10/01/2026

Dr. Erkut Borazanci, Medical Director of HonorHealth Research Institute’s Oncology Division, tells Arizona Horizon’s Ted Simons that a new pill for treating advanced pancreatic cancer “is such a huge milestone.”

Even before final FDA approval, the Research Institute was one of the first in the nation to offer this new drug, Daraxonrasib, which based on early data nearly doubles the average survival time of patients with pancreatic cancer.

“Thankfully, the company, with the FDA’s guidance, was able to offer this (drug) through an expanded access program,” Dr. Borazanci told Simons, the public affairs program’s long-time host. “These are individuals that may not have options. While it doesn’t … cure everyone with pancreas cancer, it gives them a lot greater opportunity to live longer, with a good quality of life.”

The medication’s effectiveness has been heralded ever since early test results were announced at this summer’s annual convention of the 45,000-member American Society of Clinical Oncology (ASCO), prompting a standing ovation from the thousands of cancer physicians gathered in Chicago.

Daraxonrasib was approved by the FDA on Aug. 26 for adults with metastatic pancreatic adenocarcinoma — meaning it has spread to other organs — and who have received at least one previous systemic therapy.

For more about HonorHealth Research Institute clinical trials: call 833-354-6667; or email [email protected].

09/24/2026

As part of National Advanced Practice Provider (APP) Week, Erin Pierce, a nurse practitioner in the Oncology Research Division of HonorHealth Research Institute, was a recipient at the HonorHealth APP Awards Ceremony of the “Remarkable Research and Innovation Award for Significant Contributions to the Advancement of the Profession.”

As an APP, Erin is a licensed healthcare professional trained to provide clinical services beyond traditional nursing or allied health roles.

“Since arriving to HonorHealth in 2024, she has quickly established herself as a leader within our research program, expanding her expertise across multiple oncology specialties and bringing a level of energy, purpose, and dedication that has had an immediate impact,” said Susie Harding, MSN, APRN, NP-C, Nurse Practitioner, Sub-Investigator and APP Specialty Supervisor in the Oncology Research Division.

Erin has served as a sub-investigator on more than 200 clinical trials and is among a distinguished group of APPs leading prospective early-phase studies as a primary investigator. Through her research efforts, she is helping bring promising new therapies to patients while contributing to discoveries that have the potential to shape the future of cancer care.

Erin is a champion for her APP colleagues and one of the first people to celebrate the success of others. Through mentorship, collaboration, and encouragement, she has helped foster a culture of curiosity, innovation, and excellence.

09/23/2026

Sunil Sharma, M.D., FACP, M.B.A., director of the Center for Translational Science at HonorHealth Research Institute, has been named by the Arizona Bioindustry Association (AZBio) as the Arizona Bioscience Researcher of the Year.

Dr. Sharma will be honored at the 2026 AZBio Awards, on Oct. 7 at the Phoenix Convention Center. The 23rd annual awards banquet is part of Arizona Bioscience Week, Oct. 5-9.

“Recognized for his outstanding contributions to biological research and drug discovery, Dr. Sharma exemplifies what it means to push the frontiers of modern medicine,” according to Joan Koerber-Walker, President and CEO of AZBio.

Dr. Sharma, who describes himself as a physician-scientist, said he has always been interested how basic scientific research can lead to innovation, and how new treatments and new technologies, especially now, can benefit cancer patients.

Of his award, Dr. Sharma said, “I think mostly it’s recognition for the kind of work that we’re doing and it’s hopefully a great recognition for translational science in general, that it’s important and that it can add something to the (Arizona) bioscience corridor that we’re all trying to build.”

Dr. Sharma, who heads the Research Institute’s Center for Translational Science, is honored by the Arizona Bioindustry Association

09/15/2026

At any given time, HonorHealth Research Institute is engaged in hundreds of clinical trials, especially cancer studies, which can help accelerate new treatment breakthroughs.

Beyond oncology, HonorHealth’s premier research center also studies potential advancements in other areas, including: cardiovascular, neuroscience, bariatric/gastrointestinal, and many others. These includes studies testing new drugs, devices and techniques for everything from stroke to weight loss.

Dr. Erkut Borazanci, Medical Director of HonorHealth Research Institute’s Oncology Division, and Erin Pierce, a Nurse Practitioner in the Division, recently helped 12 News reporter Ginger Jeffries explain how clinical trials work and how they can benefit patients.

For more about HonorHealth Research Institute clinical trials: call 833-354-6667; or email [email protected].

09/03/2026

HonorHealth Research Institute's Dr. Erkut Borazanci was in studio with the FOX 10 News team today to discuss the Institute's use of a new pancreatic cancer treatment that is generating excitement across the oncology community.

The Institute was one of the first in the nation to offer this new drug, Daraxonrasib, which based on early data nearly doubles the average survival time of patients with pancreatic cancer.

“The survival was over a year with this pill,” Dr. Borazanci told FOX 10 News anchors. “We hope to build upon that success with other clinical trials.”

The medication’s effectiveness has been heralded ever since early test results were announced at this summer’s annual convention of the 45,000-member American Society of Clinical Oncology (ASCO), prompting a standing ovation from the thousands of cancer physicians gathered in Chicago.

Most recently, Daraxonrasib was approved by the FDA on Aug. 26 for adults with metastatic pancreatic adenocarcinoma — meaning it has spread to other organs — and who have received at least one previous systemic therapy.

“Up until this pill's approval last week, our options outside of a clinical trial was chemotherapy,” Dr. Borazanci said. ”This is the first targeted agent against pancreas cancer.”

09/02/2026

Dr. Erkut Borazanci, Medical Director of HonorHealth Research Institute’s Oncology Division, and Erin Pierce, a Nurse Practitioner in the Division, were featured today by 12 News in a story about the Research Institute’s new efforts to treat pancreatic cancer.

The Institute was one of the first in the nation to offer this new drug, Daraxonrasib, which based on early data nearly doubles the average survival time of patients with pancreatic cancer.

Daraxonrasib was approved by the FDA on Aug. 26 for adults with metastatic pancreatic adenocarcinoma — meaning it has spread to other organs — and who have received at least one previous systemic therapy.

Pierce described her elation as being able to join Dr. Borazanci in informing a patient that the drug was having a positive effect: “That was an amazing feeling!”

Dr. Borazanci explained that the new drug targets a cancer-driving mutated form of the protein KRAS: “and helps shut down the growth of those cancer cells.”

12 News will feature HonorHealth’s clinical trials next Wednesday, Sept. 9.

For more about HonorHealth Research Institute clinical trials: call 833-354-6667 or email [email protected].

08/30/2026

A newly approved drug is giving eligible patients with advanced pancreatic cancer a new option.

Before FDA approval, HonorHealth Research Institute was among the first centers in the nation selected to provide daraxonrasib through an expanded access program, giving physicians firsthand experience with the investigational drug.

Learn more about what this milestone means for patients and the future of pancreatic cancer care:
https://honorhealthresearch.org/news-research/early-access-to-new-pancreatic-cancer-treatment-expands-hope/

08/26/2026

Extending gratitude to everyone who participated in the Fifth Annual HonorHealth Research Institute Symposium! Last week, this event brought together staff, researchers, clinicians, and grateful patients for a day of networking and collaboration.